CN115397842A - 用于急性髓系白血病(aml)的新型肿瘤特异性抗原及其用途 - Google Patents

用于急性髓系白血病(aml)的新型肿瘤特异性抗原及其用途 Download PDF

Info

Publication number
CN115397842A
CN115397842A CN202180028396.9A CN202180028396A CN115397842A CN 115397842 A CN115397842 A CN 115397842A CN 202180028396 A CN202180028396 A CN 202180028396A CN 115397842 A CN115397842 A CN 115397842A
Authority
CN
China
Prior art keywords
seq
tap
leukemia
hla
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028396.9A
Other languages
English (en)
Chinese (zh)
Inventor
克劳德·佩罗
皮埃尔·蒂伯尔
塞巴斯蒂安·勒米厄
格雷戈里·厄克斯
马里-皮埃尔·哈迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Publication of CN115397842A publication Critical patent/CN115397842A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180028396.9A 2020-04-14 2021-03-15 用于急性髓系白血病(aml)的新型肿瘤特异性抗原及其用途 Pending CN115397842A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009853P 2020-04-14 2020-04-14
US63/009,853 2020-04-14
PCT/CA2021/050340 WO2021207823A1 (en) 2020-04-14 2021-03-15 Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof

Publications (1)

Publication Number Publication Date
CN115397842A true CN115397842A (zh) 2022-11-25

Family

ID=78083452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028396.9A Pending CN115397842A (zh) 2020-04-14 2021-03-15 用于急性髓系白血病(aml)的新型肿瘤特异性抗原及其用途

Country Status (11)

Country Link
US (1) US20230287070A1 (https=)
EP (1) EP4136099A4 (https=)
JP (2) JP7822953B2 (https=)
KR (1) KR20220167288A (https=)
CN (1) CN115397842A (https=)
AU (1) AU2021256477A1 (https=)
BR (1) BR112022020376A2 (https=)
CA (1) CA3173666A1 (https=)
IL (1) IL296881A (https=)
MX (1) MX2022012758A (https=)
WO (1) WO2021207823A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114045341B (zh) * 2021-11-30 2024-03-01 中南大学 口腔黏膜下纤维化恶性进展或其所致口腔癌的早期诊断和/或预后生物标志物的应用及产品
WO2024077376A1 (en) * 2022-10-11 2024-04-18 Université de Montréal Novel tumor-specific antigens for myeloid leukemia and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016156400A1 (en) * 2015-03-31 2016-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
CN109071605A (zh) * 2016-04-06 2018-12-21 伊玛提克斯生物技术有限公司 用于aml和其他癌症免疫治疗的新型肽和肽组合物
US20190275130A1 (en) * 2014-05-09 2019-09-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
WO2020041876A1 (en) * 2018-08-30 2020-03-05 Université de Montréal Proteogenomic-based method for identifying tumor-specific antigens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
EP2576614A4 (en) * 2010-05-24 2013-11-13 Phosimmune Inc CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
SG11201507883SA (en) * 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20200967T1 (hr) * 2014-06-20 2020-10-16 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
WO2016209079A1 (en) * 2015-06-24 2016-12-29 Aimm Therapeutics B.V. Aml antigens and uses thereof
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EA201992416A1 (ru) * 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202024121A (zh) * 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190275130A1 (en) * 2014-05-09 2019-09-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
WO2016156400A1 (en) * 2015-03-31 2016-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
CN109071605A (zh) * 2016-04-06 2018-12-21 伊玛提克斯生物技术有限公司 用于aml和其他癌症免疫治疗的新型肽和肽组合物
WO2020041876A1 (en) * 2018-08-30 2020-03-05 Université de Montréal Proteogenomic-based method for identifying tumor-specific antigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EHX, GREGORY等: "Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes", 《IMMUNITY》, vol. 54, no. 4, 13 April 2021 (2021-04-13) *
LAROUCHE, JEAN-DAVID等: "Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues", 《GENOME MEDICINE》, vol. 12, no. 1, 28 April 2020 (2020-04-28) *
李姗姗等: "急性髓系白血病免疫治疗方式及研究进展", 《中国细胞生物学学报》, vol. 41, no. 12, 7 January 2020 (2020-01-07) *

Also Published As

Publication number Publication date
EP4136099A4 (en) 2024-08-07
CA3173666A1 (en) 2021-10-21
AU2021256477A1 (en) 2022-11-10
BR112022020376A2 (pt) 2022-11-22
JP2026009916A (ja) 2026-01-21
JP2023521219A (ja) 2023-05-23
US20230287070A1 (en) 2023-09-14
MX2022012758A (es) 2022-11-30
EP4136099A1 (en) 2023-02-22
JP7822953B2 (ja) 2026-03-03
IL296881A (en) 2022-12-01
WO2021207823A1 (en) 2021-10-21
KR20220167288A (ko) 2022-12-20

Similar Documents

Publication Publication Date Title
CN112639136B (zh) 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法
EP3341014A1 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
JP2026009916A (ja) 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
US20250136937A1 (en) Novel tumor-specific antigens for colorectal cancer and uses thereof
WO2025097243A1 (en) Colorectal tumor antigens and uses thereof
US20260048105A1 (en) Novel antigens for cancer and uses thereof
IL323881A (en) Novel tumor antigens for melanoma and uses thereof
CA3224907A1 (en) Novel tumor-specific antigens for cancer stem cells and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination